Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation.

Kingsbury JS, Laue TM, Klimtchuk ES, Th├ęberge R, Costello CE, Connors LH.

J Biol Chem. 2008 May 2;283(18):11887-96. doi: 10.1074/jbc.M709638200. Epub 2008 Mar 6.

2.

Recent progress in the understanding and treatment of transthyretin amyloidosis.

Sekijima Y.

J Clin Pharm Ther. 2014 Jun;39(3):225-33. doi: 10.1111/jcpt.12145. Review.

PMID:
24749898
3.

Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.

Sekijima Y, Kelly JW, Ikeda S.

Curr Pharm Des. 2008;14(30):3219-30. Review.

PMID:
19075702
4.

Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.

Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, Peterson SA.

Adv Protein Chem. 1997;50:161-81. Review.

PMID:
9338081
5.

Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.

Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):587-96. Review.

PMID:
16266291
7.

Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.

Arsequell G, Planas A.

Curr Med Chem. 2012;19(15):2343-55. Review.

PMID:
22471983
8.

Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.

Ton VK, Mukherjee M, Judge DP.

Clin Med Insights Cardiol. 2015 Jan 5;8(Suppl 1):39-44. doi: 10.4137/CMC.S15719. eCollection 2014. Review.

Supplemental Content

Support Center